Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 16 clinical trials
Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody (FORTplus)

response and progression free survival. The goal of the FORTplus trial is to prove (1) the non-inferiority of LDRT (4Gy) in a combined approach with an anti-CD20-antibody. In case of non-inferiority

  • 0 views
  • 28 Jul, 2022
  • 1 location
An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (ELM-2)

including an anti-CD20 antibody and an alkylating agent 3 according to Lugano Classification and as assessed by independent central review and local investigator evaluation

btk inhibitor
follicular lymphoma
tositumomab
cancer
diffuse large b-cell lymphoma
  • 69 views
  • 20 Sep, 2022
  • 129 locations
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

This is the study of the PI3Kδ inhibitor Zandelisib (ME-401) in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma after failure of at least 2 prior lines of systemic therapy

marginal zone lymphoma
ejection fraction
ct scan
follicular lymphoma
refractory follicular lymphoma
  • 204 views
  • 13 Mar, 2022
  • 126 locations
Evaluation of Safety and Efficacy of Allo GDA-201 NK Cells in Patients With Relapsed/Refractory B Cell NHL

with rituximab, monoclonal anti-CD20 antibody, for patients with relapsed or refractory B Cell non-Hodgkin lymphoma (NHL).

rituximab
  • 0 views
  • 17 Jun, 2022
  • 2 locations
Obinutuzumab in Marginal Zone Lymphoma

. The type II anti-CD20 antibody Obinutuzumab (OBINUTUZUMAB) has demonstrated remarkable activity in follicular lymphoma and superiority to Rituximab in combination with chemotherapy in treatment nave

platelet count
interferon
splenic marginal zone lymphoma
cancer
gastric malt lymphoma
  • 25 views
  • 08 Feb, 2022
  • 14 locations
Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas (ExoReBLy)

Diffuse large B-cell lymphomas (DLBCL) are highly aggressive and heterogeneous B-cell lymphoma that would imminently be fatal without treatment. Monoclonal anti-CD20 antibody, rituximab, in

Accepts healthy volunteers
  • 6 views
  • 12 Aug, 2022
  • 1 location
The Use of IVIG in Combination With Rituximab VS Rituximab as the First Line Treatment of Pemphigus

monoclonal anti-CD20 antibody against B-lymphocytes, as an efficacious therapy for pemphigus. Early use of rituximab was associated with better clinical outcomes, hence combination treatment of rituximab and

immunosuppressants
autoimmune disease
anti-cd20 antibody
rituximab
prednisolone
  • 79 views
  • 22 Sep, 2022
  • 1 location
Pembrolizumab in Marginalzone Lymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

toxicity and efficacy of Pembrolizumab in combination with the anti-CD20 antibody Rituximab in patients with newly diagnosed or relapsed MZL in need of treatment, who are not eligible or failed local

  • 0 views
  • 17 Sep, 2022
  • 9 locations
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

of Copanlisib in combination with the anti-CD20 antibody Rituximab in patients with newly diagnosed or relapsed MZL in need of treatment, who are not eligible or failed local therapy, following the

platelet count
rituximab
measurable disease
ct scan
splenic marginal zone lymphoma
  • 10 views
  • 21 Apr, 2022
  • 12 locations
CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children

. Study of adding anti-CD20 antibody (rituximab) with chemotherapy: CD20 is found to be expressed in 40-50% of B-lineage ALL, and rituximab has been studied in adult ALL with superior

  • 0 views
  • 23 Feb, 2022
  • 1 location